Saturday - February 7, 2026
Nucala Approved by the European Commission for the Treatment of Chronic Obstructive Pulmonary Disease
February 07, 2026
LONDON, England, Feb. 7 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Feb. 6, 2026:

* * *

Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD)

* Approval based on results from MATINEE showing significant reduction in the rate of moderate/severe exacerbations versus placebo

* Nucala is the first and only monthly biologic i . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products